Core Viewpoint - The development of biomanufacturing is crucial for enhancing new productive forces in China, with the potential to account for one-third of global manufacturing output by the end of the century, creating a market worth $30 trillion [4]. Group 1: Biomanufacturing Industry Insights - Biomanufacturing is becoming a focal point in national strategic competition, with the U.S. aiming to replace 90% of traditional plastics with bio-based products within 20 years, and the EU implementing a carbon border adjustment mechanism by 2027 [4]. - The technology demonstrates significant potential in addressing resource and environmental challenges, such as using a 50 cubic meter bioreactor to produce artemisinin, which saves 30,000 acres of arable land [4]. - Each ton of bio-based plastic can reduce carbon dioxide emissions by 0.6 tons compared to traditional plastics, contributing to carbon neutrality goals [4]. Group 2: Applications and Innovations - Revolutionary breakthroughs in biomanufacturing are emerging, including the development of biological pheromones for precise pest control, which can replace high-residue pesticides [5]. - The cost of products like hyaluronic acid has significantly decreased due to biomanufacturing, and carbon dioxide is being explored as a third-generation raw material [5]. - The integration of artificial intelligence accelerates innovation, enabling the industrial production of scarce components like catechin from green tea [5]. Group 3: Challenges and Recommendations - Despite holding 70% of global fermentation capacity, the biomanufacturing industry in China faces challenges such as a lack of proprietary strains and limitations in core software tools [5]. - There is a call for enhanced top-level design to focus on cutting-edge areas like carbon dioxide bioconversion and future food manufacturing, aiming to address both green chemical alternatives and protein supply security [5].

2 0 2 5年9月2 5日至2 7日，中国香料香精化妆品行业年会暨精品博览会（2 0 2 5CAME）在南京 国际博览中心顺利召开。 本次大会以"科技·品牌·共进"为主题，汇聚百家企业、5 0 0多个品牌、千余款新品以及1 4个国 际组织，集中展示中国香妆行业从原料创新、品牌升级到可持续发展的一系列成果。 在当前全球化妆品市场增长放缓、竞争内卷化的背景下，2 0 2 5CAME试图为行业寻找一份确 定性答卷。企业、品牌及国际组织的深度参与，不仅体现了展会本身的号召力，更反映出整个 产业寻求系统性突破的共识。 从 核 心 技 术 攻 关 到 品 牌 价 值 重 构 ， 从 单 点 竞 争 到 生 态 共 建 ， 中 国 香 妆 产 业 正 通 过 深 化 科 技 驱 动、重塑品牌逻辑、构建协同网络，培育新质生产力，重塑其在全球价值链中的话语权。 本届CAME释放出一个明确信号：科技创新已不再只是企业的营销标签，而是成为支撑产业可 持续发展的硬核能力。在原料研发、检测评价、研发范式等关键环节，系统性、源头性的创新 正在密集出现。 在原料创新层面，"自主可控"成为核心议题。 过去严重依赖进口的化妆品活性原料领域， ...

自5月初起，医美领域围绕重组胶原蛋白与透明质酸的产业讨论持续升温。华熙生物官微发布题为《概 念总在重演，科技永远向前》的文章受到行业关注。该篇文章就部分研报提及的关于透明质酸的片面观 点，提出科学层面的不同看法。 对于此次公开交流，华熙生物相关负责人在接受中国证券报记者采访时表示，公司上市以来与研究机构 保持着长期良性互动，此次针对部分研报观点的回应，源于对科学事实的尊重——上市公司与研究机构 同为资本市场的重要参与主体，更应基于科学本质传递信息，共同维护资本市场的理性生态。 关注新兴技术需以科学为基础 此次行业讨论的起点，源于一家胶原蛋白企业在港股上市时，其招股说明书中对重组胶原蛋白与透明质 酸的功效及市场价值进行了对比表述。这一表述被部分研报引用后，形成了"重组胶原蛋白更具优势"的 片面观点。在市场对新兴概念的关注下，相关企业获得较高市场关注度，股价呈现阶段性上升。 随后，该片面观点伴随部分传播渠道的扩散，逐渐引发消费市场对透明质酸功效的认知偏差，也对透明 质酸这一国内优势产业的市场信任基础造成影响。 华熙生物表示，这类观点的形成，反映出部分研究机构从业人员对透明质酸产业的认知有待深化。事实 上，透明质酸 ...

Core Viewpoint - The investment in Saint Nor Pharmaceutical is a strategic move for the company to enhance its position in the biopharmaceutical sector, particularly in innovative drug development and to leverage synergies in its core business areas [1][2]. Investment Strategy - The investment amount is approximately HKD 138 million, funded entirely from the company's own resources, and will be paid in installments as per the agreement [2]. - The company recognizes the long development cycles and high risks associated with small nucleic acid drug research and has established risk control and exit arrangements through the investment agreement [2]. Business Development - The company reported a steady increase in sales revenue from its innovative hyaluronic acid products and other bioactive substances, accounting for over 23% of total sales in the first half of 2025 [3]. - Six new bioactive raw material products have been launched, including Hyatrue® cross-linked sodium hyaluronate and BloomColla® recombinant type III humanized collagen [3]. Operational Adjustments - The company has undergone systematic adjustments in its operational philosophy and business direction since March 2025, leading to a significant reduction in sales expense ratio by 12.46 percentage points year-on-year in Q2 [4]. - The focus is on transforming consumer products based on long-term technological barriers and scientific assets, particularly in the fields of cell biology and glycoscience [5]. Organizational Changes - The company is shifting away from hiring external "professional operators" and is instead selecting and training entrepreneurial talents who align with the company's values for management positions [6]. - A one-time management expense of approximately CNY 29 million was incurred during this transition, aimed at laying a solid foundation for long-term development [6]. Scientific Communication - The company is committed to reshaping its scientific image and defending scientific values, aiming to establish a rigorous scientific communication system to counter misinformation in the industry [6].

Group 1 - The event "Exploring the Trillion-Yuan Biomanufacturing Synthesis Code" aims to showcase Shandong's biomanufacturing innovations and industry advantages, enhancing brand influence and accelerating new productivity development [1][4] - Shandong is recognized as a leader in biomanufacturing in China, with the most diverse product types and significant international standing [4][11] - The biomanufacturing industry in Shandong has achieved a unique advantage characterized by scale, complete supply chains, and active innovation, with several key products holding the world's largest production capacity [8][11] Group 2 - The provincial government plans to strengthen policy support and complete the "14th Five-Year" development plan for the biomanufacturing industry by the end of the year [8] - The industry is projected to exceed a production value of 680 billion yuan in 2024, with significant contributions to green products and carbon emission reductions [11] - Leading companies in the biomanufacturing sector, such as Huaxi Biotechnology Co., Ltd. and Shandong Bailong Chuangyuan Biotechnology Co., Ltd., shared their achievements and experiences during the event [16]

英国剑桥大学研究团队发现，"冻结"大脑中的关键分子——透明质酸，可有效阻止脑癌细胞扩散。这一 成果有望为脑癌治疗提供新方向，相关研究论文发表于最新一期《皇家学会开放科学》杂志。 透明质酸是一种糖状聚合物，构成了大脑中大部分支持结构。团队发现，癌细胞正是借助这种分子的柔 韧性，才能附着于其他癌细胞表面的受体，进而触发扩散机制。若将透明质酸"冻结"在原位、限制其灵 活性，便可使癌细胞停止移动、无法侵入周围组织，实现"重新编程"。 脑癌治疗一直面临严峻挑战，即便手术切除肿瘤，残留的癌细胞仍可能在数月内再生。现有药物难以穿 透血脑屏障，放疗也只能延缓而不能阻止复发。最新研究的创新之处在于，不直接攻击肿瘤细胞，而是 改变其周围的细胞外基质，从环境上遏制癌细胞扩散。 借助核磁共振光谱技术，团队观察到透明质酸分子会扭曲成特定形态，与癌细胞表面的CD44受体紧密 结合，从而驱动扩散。一旦让透明质酸分子交联并"冻结"，扩散信号即被关闭。即使透明质酸浓度较 低，该机制依然有效，这说明癌细胞并非被物理禁锢，而是被诱导进入休眠状态。 这一发现也解释了为何胶质母细胞瘤常在手术部位复发，因为术后水肿可稀释透明质酸，增强其柔韧 性，反而促 ...

Core Viewpoint - The article emphasizes the need for companies, particularly Huaxi Biological, to adapt and innovate in a rapidly changing market environment, focusing on scientific evidence and technological strength to regain market leadership in skin science innovation [4][5][6]. Group 1: Company Strategy and Leadership - Zhao Yan, the leader of Huaxi Biological, acknowledges past mistakes in market awareness and emphasizes the importance of a strong operational team to navigate the competitive landscape [3][4]. - The company is shifting its focus from merely being known for hyaluronic acid to positioning itself as a synthetic biotechnology firm with a robust research and development foundation [5][16]. - Huaxi Biological aims to stabilize its core business while exploring new product categories, leveraging its significant investment in a large-scale synthetic biology pilot platform [6][26]. Group 2: Marketing and Brand Strategy - The company has faced declining revenue and profit margins in its functional skincare segment from 2022 to 2024, prompting a reevaluation of its marketing strategies [8]. - Zhao Yan has restructured the brand division to emphasize skin science and health, moving away from reliance on high-profile influencers to a more diversified marketing approach [9][10]. - The company is focusing on scientific communication in its marketing efforts, aiming to clarify the benefits of its products based on research data rather than vague marketing jargon [10][13]. Group 3: Research and Development Focus - Huaxi Biological has invested heavily in R&D, establishing a state-of-the-art research center to support its product development and quality assurance processes [11][18]. - The company is expanding its research into glycoscience and cell biology, with a focus on developing new materials that can address aging and tissue regeneration [19][20]. - The strategic decision to develop a range of glycan-based products reflects the company's commitment to innovation and its understanding of market demands for new anti-aging solutions [20][21]. Group 4: Market Position and Future Outlook - The company is positioned to capitalize on the growing demand for synthetic biology products, with a focus on overcoming the challenges of scaling production from laboratory to market [23][24]. - Huaxi Biological's investment in a flexible pilot platform is seen as a critical infrastructure for the synthetic biology industry, enabling faster and more efficient product development [26]. - The company aims to maintain its entrepreneurial spirit and adaptability in the face of market fluctuations, emphasizing the importance of scientific integrity over marketing hype [27].

Core Insights - The core viewpoint of the articles revolves around the challenges and strategic shifts faced by Huaxi Biological, particularly under the leadership of Zhao Yan, as the company aims to regain its market position in the highly competitive beauty and medical aesthetics industry while leveraging its scientific capabilities in synthetic biology [1][2][9]. Group 1: Company Challenges and Strategic Shifts - Huaxi Biological's revenue and gross margin from functional skincare products have been declining from 2022 to 2024, impacting market confidence [3]. - Zhao Yan acknowledges internal issues in team building and organizational capabilities that have led to ineffective marketing investments, emphasizing the need for a more scientific and rational approach to market communication [4][8]. - The company is transitioning from reliance on high-profile influencers to a more diversified marketing strategy, focusing on mid-tier influencers to enhance brand presence and consumer engagement [4][5]. Group 2: R&D and Technological Advancements - Huaxi Biological has invested significantly in R&D, with a state-of-the-art research center in Jinan, equipped with advanced analytical instruments to support its raw material research and quality control [6][11]. - The company is expanding its product development into various biological materials, including collagen and other glycan-based substances, leveraging its expertise in synthetic biology [9][12]. - The establishment of a large-scale synthetic biology pilot platform in Tianjin, costing 3 billion yuan, aims to bridge the gap between laboratory research and large-scale production, addressing the challenges of scaling up biomanufacturing processes [18]. Group 3: Market Position and Future Outlook - Huaxi Biological's core product, hyaluronic acid, remains a significant revenue driver, but the company is also focusing on new concepts in the market, such as recombinant collagen, to meet evolving consumer demands [9][10]. - The company is positioning itself as a leader in synthetic biology, with a strategic focus on developing a comprehensive ecosystem that includes partnerships with academic institutions and other biotech firms [11][13]. - Zhao Yan's leadership is characterized by a return to entrepreneurial spirit, aiming to replicate the success of hyaluronic acid across multiple product lines, thus enhancing the company's growth potential in the biomanufacturing sector [14][16].

Core Viewpoint - Despite facing overall performance pressure in the first half of 2025, Huaxi Biological's strategic adjustments have begun to yield results, indicating a potential turning point in profitability [2][3]. Financial Performance - In the first half of 2025, Huaxi Biological achieved operating revenue of 2.261 billion yuan, with a net profit attributable to shareholders of 221 million yuan, and a net profit excluding non-recurring gains and losses of 174 million yuan. The overall performance did not show growth [2]. - In Q2 2025, the company reported operating revenue of 1.183 billion yuan, a year-on-year decline of 18.44%. However, the net profit attributable to shareholders increased by 20.89% to 119 million yuan, marking the first year-on-year and quarter-on-quarter increase in net profit margin since Q1 2024 [2]. Strategic Transformation - The return of the General Manager to the front line has driven significant changes, shifting the company's strategy from "scale expansion" to a "benefit-oriented development model" centered on scientific research and innovation [3]. - Huaxi Biological aims to continue focusing on technological innovation to expand the application of synthetic biology and optimize its business structure for high-quality development [3]. R&D Investment - R&D expenses increased by 15.25%, focusing on three key areas: synthetic biology technology, industrialization of recombinant collagen, and microecological preparations, with a 30% improvement in strain modification efficiency [4]. - The company is actively developing new bioactive substances using cutting-edge synthetic biology technologies and has initiated 34 skin science innovation R&D projects and 17 nutrition science innovation R&D projects during the reporting period [4]. Industrial Application and Future Growth - Huaxi Biological is applying its leading synthetic biology manufacturing capabilities across three major sectors, establishing a complete R&D chain from basic research to technology transfer and industrial application [6]. - The company has completed process validation for its sterile HA production line and is advancing the national synthetic biology technology innovation center in Tianjin, aiming to overcome the "scaling up" bottleneck in biomanufacturing [6]. - The establishment of Huaxi Tang'an Biotechnology Co., Ltd. is noteworthy, as it utilizes synthetic biology technology for the precise synthesis of heparin polysaccharides, positioning the company to transition the heparin industry from "animal resource dependence" to "green biomanufacturing" [6].

Core Insights - The company has made significant progress in its "Quality Improvement and Efficiency Enhancement" initiative, focusing on core business areas, operational management, technological innovation, corporate governance, and investor returns [1][5][6] Group 1: Business Performance - The company reported a revenue of 1.183 billion yuan in Q2 2025, a year-on-year decrease of 18.44%, while net profit attributable to shareholders was 119 million yuan, an increase of 20.89% [5] - For the first half of 2025, total revenue was 2.261 billion yuan, down 19.57% year-on-year, with net profit attributable to shareholders declining by 35.38% [5] - The company’s inventory turnover days decreased from 391 days in Q1 2025 to 321 days in Q2 2025, indicating improved operational efficiency [5] Group 2: Research and Development - The company has reduced its R&D projects by 88 compared to 2024, focusing on high-barrier raw materials and medical terminal businesses [2][5] - R&D expenses for the first half of 2025 were approximately 231 million yuan, representing a 15.25% increase year-on-year, with R&D expenses accounting for 10.22% of total revenue [24] - The company has obtained 293 new authorized intellectual property rights, including 33 invention patents, as part of its ongoing innovation efforts [24] Group 3: Market Strategy - The company is focusing on high-barrier technology asset transformation and enhancing its consumer goods business advantages, particularly in the fields of aging intervention and tissue regeneration [2][5] - The company has launched new products, including injection-grade Hyatrue cross-linked sodium hyaluronate and BloomColla recombinant type III humanized collagen, to strengthen its product matrix [7][26] - The company aims to optimize its brand communication model, shifting from a sales volume-driven approach to an efficiency-driven strategy [2][5] Group 4: Organizational Changes - The company is restructuring its organizational and talent systems, focusing on selecting and cultivating entrepreneurial talents aligned with its values [3][4] - Management expenses increased by approximately 29 million yuan due to organizational upgrades, impacting short-term profits but laying a foundation for long-term growth [4] Group 5: Supply Chain and Quality Management - The company is enhancing its global supply chain resilience and optimizing production efficiency through automation and digital systems [20][21] - A quality insight mechanism has been established to convert scattered quality information into valuable insights, driving continuous quality improvement [21] Group 6: Sustainability and Governance - The company is implementing an ESG management system to promote low-carbon transformation across its value chain [30][31] - The governance structure has been revised to align with the latest regulatory requirements, ensuring compliance and operational efficiency [32][33]